{
  "success": true,
  "sourceFile": "C:\\Users\\panik\\Documents\\GitHub\\Protcol2USDMv3\\input\\trial\\NCT02493868_SUSTAIN1\\NCT02493868_SUSTAIN1_SAP.pdf",
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39
  ],
  "modelUsed": "gemini-3-flash-preview",
  "sapData": {
    "analysisPopulations": [
      {
        "id": "pop_1",
        "name": "All Enrolled Analysis Set",
        "text": "The All Enrolled analysis set includes all subjects who sign the informed consent form.",
        "populationType": "Safety",
        "instanceType": "AnalysisPopulation",
        "label": "All Enrolled",
        "populationDescription": "The All Enrolled analysis set includes all subjects who sign the informed consent form.",
        "criteria": "Signed informed consent form"
      },
      {
        "id": "pop_2",
        "name": "Full Analysis Set",
        "text": "The Full Analysis Set (FAS) includes all randomized subjects who received at least 1 dose of intranasal study medication and at least 1 dose of oral antidepressant during the maintenance phase. Transferred-entry subjects who continue to receive an oral antidepressant plus intranasal placebo will not be included in the full analysis sets.",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "FAS",
        "populationDescription": "The Full Analysis Set (FAS) includes all randomized subjects who received at least 1 dose of intranasal study medication and at least 1 dose of oral antidepressant during the maintenance phase. Transferred-entry subjects who continue to receive an oral antidepressant plus intranasal placebo will not be included in the full analysis sets.",
        "criteria": "Randomized AND received >=1 dose of intranasal study medication AND received >=1 dose of oral antidepressant during maintenance phase"
      },
      {
        "id": "pop_3",
        "name": "Interim Full Analysis Set",
        "text": "The interim Full Analysis Set (FAS) includes all randomized subjects who received at least 1 dose of intranasal study medication and at least 1 dose of oral antidepressant during the maintenance phase and were randomized at least 22 weeks before the interim data cut-off date.",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "Interim FAS",
        "populationDescription": "The interim Full Analysis Set (FAS) includes all randomized subjects who received at least 1 dose of intranasal study medication and at least 1 dose of oral antidepressant during the maintenance phase and were randomized at least 22 weeks before the interim data cut-off date.",
        "criteria": "Randomized AND received >=1 dose of intranasal study medication AND received >=1 dose of oral antidepressant AND randomized >=22 weeks before interim data cut-off"
      },
      {
        "id": "pop_4",
        "name": "Safety Analysis Set",
        "text": "The safety analysis set for a phase (e.g., induction, optimization, maintenance, or follow-up) includes all subjects who received at least 1 dose of intranasal study medication or 1 dose of oral antidepressant during that phase.",
        "populationType": "Safety",
        "instanceType": "AnalysisPopulation",
        "label": "SAF",
        "populationDescription": "The safety analysis set for a phase (e.g., induction, optimization, maintenance, or follow-up) includes all subjects who received at least 1 dose of intranasal study medication or 1 dose of oral antidepressant during that phase.",
        "criteria": "Received >=1 dose of intranasal study medication OR >=1 dose of oral antidepressant during the specific phase"
      },
      {
        "id": "pop_5",
        "name": "Follow-up Analysis Set",
        "text": "The follow-up analysis set includes all subjects who enter the follow-up phase.",
        "populationType": "Safety",
        "instanceType": "AnalysisPopulation",
        "label": "FU Set",
        "populationDescription": "The follow-up analysis set includes all subjects who enter the follow-up phase.",
        "criteria": "Entered the follow-up phase"
      }
    ],
    "characteristics": [
      {
        "id": "char_1",
        "name": "Demographics",
        "code": "DEMOGRAPHICS",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Demographics",
        "dataType": "Categorical/Numeric",
        "instanceType": "Characteristic",
        "description": "Age, gender, race, and ethnicity"
      },
      {
        "id": "char_2",
        "name": "Baseline Characteristics",
        "code": "BASELINE_CHARACTERIS",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Baseline Characteristics",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Baseline MADRS total score, BMI, and psychiatric history"
      }
    ],
    "summary": {
      "populationCount": 5,
      "characteristicCount": 2
    }
  }
}